The Shotlee Journal
Browse Shotlee articles about Ozempic.
Showing 9 / 1083 Ozempic articles
Weight loss medications, specifically GLP-1 receptor agonists, have been associated with an increased risk of chronic cough in individuals with type 2 diabetes. A recent study compared patients taking GLP-1s with those on other diabetes treatments, revealing a notable link between the drugs and persistent coughing.
A biopharmaceutical firm is planning a pilot study using GLP-1 agonists on obese cats, similar to drugs like Ozempic and Wegovy used for human weight loss. The treatment involves microchip implants that release the drug over six months. Similar trials are planned for dogs.
Research indicates that discontinuing GLP-1 medications around conception or in early pregnancy might carry risks. The study links stopping these drugs to increased gestational weight gain and adverse pregnancy outcomes. Experts emphasize the need for further investigation to fully understand the implications.
In 2025, a noticeably thinner, but gaunt, face became a common sight in Hollywood. This was attributed to the use of rapid weight loss drugs, which led to a condition known as 'Ozempic face'. The drugs affected facial fat and skin health, causing sagging and impacting rejuvenation.
An Indian court has granted Dr. Reddy's Laboratories Ltd permission to manufacture and export generic versions of Novo Nordisk's diabetes and obesity medications. This decision comes before the global patent expirations in 2026. The ruling allows export to countries without patent protection.
Novo Nordisk is set to introduce Ozempic in India, complementing their existing semaglutide product line. This launch occurs amidst strong competition from Eli Lilly's Mounjaro. The new medication may also be prescribed for other health conditions.
More and more fit individuals are turning to microdoses of GLP-1s, drawn by potential health benefits beyond weight loss. While some see it as a proactive approach to longevity, experts caution about the lack of research and potential risks.
Eli Lilly has announced price cuts for its weight loss medication Zepbound, aiming to improve accessibility for patients. The company is also seeking to increase the use of its digital healthcare platform, LillyDirect, through these changes.
The World Health Organization (WHO) has issued new guidelines advocating for the use of GLP-1 drugs in the treatment of obesity. These guidelines suggest that GLP-1 therapies can be used long-term by adults, excluding pregnant women, when combined with intensive behavioral therapy.
